The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Ben Lamm's Astromech Secures $30 Million to Advance AI-Biotechnology Innovation

Funding underscores strong investor interest in AI applications for life sciences.

AUSTIN, TX / ACCESS Newswire / September 23, 2025 / Entrepreneur Ben Lamm, co-founder of Colossal Biosciences, has announced the successful close of a $30 million funding round for his new company, Astromech, highlighting growing investor confidence in the convergence of artificial intelligence and biotechnology.

Astromech is incorporated in Delaware and is currently operating in stealth mode. The company is developing proprietary AI technologies aimed at advancing research and development in biotechnology. Lamm is partnering with George Church, a Harvard researcher with deep expertise in genetics and synthetic biology, to build both the scientific and operational foundation of the venture.

Astromech's funding round places the company among well-capitalized early-stage AI startups, providing resources for technology development and business operations. The raise reflects a broader trend in which venture capital firms are showing increased interest in startups applying artificial intelligence to biological research challenges, pharmaceutical development, and healthcare applications.

Lamm's background with Colossal Biosciences-which focuses on de-extinction and cutting-edge genetic science-has provided added credibility with investors evaluating opportunities in the emerging AI-biotech sector.

About Astromech

Astromech is an artificial intelligence company focused on the application of advanced computational technologies to biotechnology and life sciences research. Incorporated in Delaware and currently operating in stealth mode, the company is developing proprietary platforms designed to accelerate progress in genetic research, pharmaceutical development, and related fields.

About Ben Lamm

Ben Lamm is a serial technology entrepreneur and the co-founder of Colossal Biosciences, a biotechnology company focused on de-extinction and genetic innovation. Lamm specializes in launching and scaling technology ventures at the intersection of science and advanced computing.

Contact:
Elizabeth Lodge
info@astromech.com

SOURCE: Astromech



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.